Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of VCT220 in adults with overweight or obesity and hypertension
CTR20260909Phase 2Active
- Sponsor
- Wentai Pharmaceutical
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VCT220 in essential hypertension, Overweight, obesity, sponsored by Wentai Pharmaceutical. Started Apr 2026; status: active.
02
Drugs
VCT220
03
Conditions
essential hypertensionOverweightobesity
Beyond the preview
Go deeper on CTR20260909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260909.